Researchers in the United Kingdom have initiated a clinical trial designed to test multiple medications simultaneously in people with Alzheimer’s disease. The study, termed AD-SMART, represents a platform trial approach that allows several treatments to be evaluated at once, with results compared against a control group receiving placebo. This methodology has the potential to significantly reduce the time required to identify effective therapies, as ineffective drugs can be withdrawn quickly and replaced with new candidates rather than following the traditional one-drug, one-trial model.
The initial phase of the trial will evaluate two repurposed medications: metformin, which is currently prescribed for type 2 diabetes, and atomoxetine, used to treat attention deficit hyperactivity disorder. An international panel of experts selected these drugs based on evidence suggesting they may help reduce brain inflammation, a process believed to contribute to neurodegeneration. The study aims to determine whether these medications can reduce symptoms such as memory and thinking difficulties while helping patients maintain quality of life.
The trial will recruit approximately 1,200 participants with mild to moderate Alzheimer’s disease across more than 30 sites throughout the UK. Participants will undergo regular health assessments including cognitive testing to measure treatment effectiveness. Researchers project that evaluation of the initial drugs will be completed by 2030, with additional treatments expected to be added during this period. Sites in Cambridgeshire, Surrey, London, Southampton, and Edinburgh are already enrolling patients.
Alzheimer’s affects approximately 600,000 people in the UK and represents the most prevalent form of dementia. The trial is led by the UK Dementia Research Institute and Alzheimer’s Research UK, with support from multiple national research and health organizations. Officials emphasize that identifying new treatment options is urgent for people living with the disease.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI